
Psychedelics biopharma company Reunion Neuroscience Inc. (NASDAQ:REUN) reported its business update and fiscal results for the second quarter ended September 30, 2022.
Reunion’s president and CEO Greg Mayes stated that the company has consolidated as an independent company and is “well positioned to round out the year in preparation for what promises to be an exciting 2023.”